Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 9:24:818-826.
doi: 10.12659/msm.906274.

Investigation of Adipose Tissue Fatty Acid Composition in Men with Uronephrolithiasis and Metabolic Syndrome

Inga Bikulčienė  1 , Laima Vasiliauskaitė  1 , Zita Aušrelė Kučinskienė  1 , Arvydas Kaminskas  1 , Vaiva Hendrixson  1
Affiliations

Investigation of Adipose Tissue Fatty Acid Composition in Men with Uronephrolithiasis and Metabolic Syndrome

Inga Bikulčienė et al. Med Sci Monit. .

Abstract

BACKGROUND Fatty acids (FA) and their metabolites are closely related to some mechanisms involved in the development of uronephrolithiasis. The aim of this study was to evaluate the relationship between FA composition and type of kidney stones. MATERIAL AND METHODS Abdominal adipose tissue fatty acid methyl esters of 71 men with nephrolithiasis were identified by GC/MS, and the type of kidney stones was identified using FTIR infrared spectroscopy. Patients were divided into groups according to diagnosis of metabolic syndrome (MS) and type of kidney stone. The composition of FA was compared within different groups of patients with different types of kidney stones and between the patients and healthy individuals (control group) (n=100). RESULTS Individuals with nephrolithiasis had a significantly higher level of monounsaturated fatty acids (MUFA) and a lower level of polyunsaturated fatty acids (PUFA) versus healthy individuals. Patients with MS had a higher level of 18: 1ω9 and a lower level of 16: 1ω7 than patients without MS. Individuals with nephrolithiasis, but without MS, had a higher level of saturated fatty acids (SFA) compared to controls. The level of PUFA was higher in the control group (p<0.0001) compared to individuals with uronephrolithiasis, with or without MS. PUFA, ω - 6 PUFA, and 18: 2ω6 were higher in patients with calcium-based kidney stones without MS versus patients with uric acid kidney stones with MS. CONCLUSIONS The levels of MUFA were significantly higher and the levels of PUFA were significantly lower in patients with uronephrolithiasis compared to controls.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None.

Figures

Figure 1
Figure 1
Doistribution of this study population.
Figure 2
Figure 2
Diagram represents the percentage distribution of patients with uronephrolithiasis by type of kidney stones and MS. N=71.
Figure 3
Figure 3
Box plots represent comparison of percentage of total PUFA between patients with uric acid kidney stones and MS, and the patients with calcium-based kidney stones without MS. P=0.037. N=71. PUFA – polyunsaturated fatty acid.
Figure 4
Figure 4
Box plots represent comparison of percentage of ω6 PUFA between patients with uric acid kidney stones and MS, and the patients with calcium-based kidney stones without MS. P=0.042. N=71. * – Omega; PUFA – polyunsaturated fatty acid.
Figure 5
Figure 5
Box plots represent comparison of percentage of 18: 2 ω6 between patients with uric acid kidney stones and MS, and the patients with calcium-based kidney stones without MS. P=0.042. N=71. * – Omega; PUFA – polyunsaturated fatty acid.
Figure 6
Figure 6
Box plots represent comparison of percentage of total MUFA between all groups of patients and the control group. P<0.0001. N=171. MUFA – monounsaturated fatty acids.
Figure 7
Figure 7
Box plots represent comparison of percentage of total PUFA between all groups of patients and the control group. P<0.0001. N=171. PUFA – polyunsaturated fatty acid.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens. 2008;17:304–9. - PubMed
    1. Richman K, O’Bell J, Pareek G. The growing prevalence of kidney stones and opportunities for prevention. R I Med J. 2014;97(12):31–34. - PubMed
    1. Romero V, Akpinar H, Assimos DG. Kidney stones: A global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010;12(2/3):e86–96. - PMC - PubMed
    1. Bagga HS, Chi T, Miller J, Stoller ML. New insights into the pathogenesis of renal calculi. Urol Clin North Am. 2013;40(1):1–12. - PMC - PubMed
    1. Moe OW. Kidney stones: Pathophysiology and medical management. Lancet. 2006;367:333–44. - PubMed